Last updated: February 15, 2026
Overview of Product Data
- Product Name: Xyrem (Sodium Oxybate)
- NDC: 00173-0887
- Indications: Treatment of narcolepsy with cataplexy in adults and pediatric patients
- Formulation: Oral solution, 500 mg/mL
- Approval Date: 2002 by the FDA
- Manufacturer: Jazz Pharmaceuticals
Market Landscape
Market Size
The U.S. narcolepsy treatment market has grown due to increasing diagnoses and expanding indications. The primary competitor for Xyrem is lower-priced generics, although Xyrem retains a significant share driven by brand recognition and FDA orphan drug exclusivity.
- Estimated U.S. Market Size (2022): $600 million
- Expected CAGR (2022-2027): 4-6%
Key Market Drivers
- Increase in diagnosed cases: Data indicates a rise from 137,000 cases (2020) to an estimated 172,000 (2022).
- Expanded indications: Use in additional sleep disorders and off-label uses influences sales.
- Orphan drug status: Provides market exclusivity until 2027, limiting generic competition.
Competitive Landscape
| Player |
Market Share |
Key Products |
Status |
| Jazz Pharmaceuticals |
~85% |
Xyrem |
Monopoly until 2027 |
| Generic Manufacturers |
Limited |
Pending approval |
Potential disruption |
| New Entrants |
None confirmed |
N/A |
Future risk |
Pricing Trends and Projections
Current Pricing (2023)
- Average Wholesale Price (AWP): $30 per mL
- Average Daily Dose: 4.5 g (~9 mL)
- Monthly Cost: Approximately $270 per patient
- Annual Revenue per Patient: ~$3,240
Price Drivers
- Regulatory exclusivity: Maintains current high prices until 2027.
- Manufacturing costs: Custody of a complex formulation; minimal reductions expected before patent expiration.
- Market dynamics: Competition from generics could decrease prices afterward.
Price Projections (2023–2030)
| Year |
Estimated Price per mL |
Comments |
| 2023 |
$30 |
Premium pricing, lacks generics |
| 2024 |
$28 |
Slight pressure from upcoming generics |
| 2025 |
$25 |
Increased competition expected |
| 2026 |
$20 |
Before patent expiry, potential discounts |
| 2027+ |
$10–15 |
Generics enter, significant price erosion |
Patent and Regulatory Outlook
- Market exclusivity: Until 2027, post which generics could significantly influence pricing.
- Patent challenges: Pending or expected challenges might accelerate generic entry.
- FDA approval process for generics: Likely to take 2-3 years, potential entry by multiple competitors.
Investment and R&D Implications
- R&D investments directed toward new formulations or delivery mechanisms could mitigate post-2027 price erosion.
- Market expansion into pediatric and possibly other sleep-related indications holds potential for revenue growth before patent expiry.
Key Takeaways
- The current dominant position of Xyrem is supported by orphan drug exclusivity until 2027.
- Pricing remains high, driven by manufacturing complexity and lack of active competition.
- Market entry of generics around 2027 is foreseeable, likely resulting in sharp price declines.
- The market is expected to grow modestly at 4-6% annually until patent expiration, driven by increasing diagnosis rates.
- Strategies focusing on pipeline diversification and biosimilar development may influence future pricing dynamics.
FAQs
1. When will generics likely enter the market for NDC 00173-0887?
Generics could enter by 2027, coinciding with expiration of Jazz Pharmaceuticals’ market exclusivity.
2. How will generic entry affect the drug’s price?
Historical patterns suggest prices could drop 50-70% post-generic entry, potentially bringing the per mL cost to $8–12.
3. What are the key factors influencing Xyrem’s current high price?
Limited competition, complex manufacturing, and orphan drug status contribute to high pricing.
4. Are there ongoing R&D efforts to extend Xyrem’s patent life?
No significant efforts are publicly documented; focus appears to be on pipeline development and new formulations.
5. How might new indications impact the market size?
Expansion into additional sleep and neurological disorders could increase the market size, offsetting revenue declines from generics temporarily.
References
- U.S. Food and Drug Administration (FDA). Xyrem (sodium oxybate) approval details. 2002.
- IQVIA. U.S. Market Trends Reports, 2022.
- Jazz Pharmaceuticals. Annual Reports and Investor Presentations, 2022.
- Market Research Future. Sleep Disorder Drug Market Analysis, 2022.
